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BACKGROUND—A growing body of evidence suggests that long-term survivors with one of
the more common forms of adult cancer report similar quality of life (QOL) to the general
population. However, specific concerns have been identified (sexual dysfunction, fatigue, distress)
in this population. Also, less is known about survivors of adult non-Hodgkin lymphoma (NHL), a
disease often marked by alternating periods of disease and remission. Therefore, this study
compares the QOL status of individuals who report having active NHL with those who are
disease-free short-term (2–4 years post-diagnosis; STS) and long-term (≥5 years post-diagnosis;
LTS) survivors.
METHODS—Eligible survivors completed a mailed survey with validated measures: physical
and mental health status, SF-36; cancer-related QOL, FACT-LYM; and self-reported impact of
cancer, IOC. Other data were collected to examine as correlates.
RESULTS—Seven-hundred and sixty one survivors identified from two NC cancer registries
participated. Subjects averaged 10.4 (range, 2–44) years post-diagnosis and 62.7 (range, 25–92)
years of age. Survivors with active disease (n=109) demonstrated worse physical and mental
health functioning, QOL, and less positive and more negative impacts of cancer when compared to
disease-free survivors (n=652; all P≤.01). No significant differences were found between STS and
LTS.
CONCLUSIONS—While NHL patients with active disease reported more negative outcomes
when compared to off-treatment survivors, length of time since diagnosis did not appear to matter
with regard to outcomes for STS and LTS. In addition, mixed results from comparisons to general
population norms suggest the need for supportive care for this diverse survivorship group.
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A growing body of evidence suggests that long-term survivors who were diagnosed and
treated for one of the more common forms of adult cancer report quality of life (QOL)
similar to that of the general population.1–4 However, specific areas of unresolved concern
have been identified in this population, including sexual dysfunction,3,5,6 low energy level
and fatigue,1,7,8 and post-traumatic stress (PTS).9–12 Further, several studies have
demonstrated positive outcomes associated with having cancer, such as greater appreciation
for life, closer personal relationships, and deeper spiritual understanding (post-traumatic
growth).6
Less is known about the health status and QOL specific to survivors of adult non-Hodgkin
lymphoma (NHL), the sixth most common cancer in the US. NHL is a heterogeneous group
of cancers of the lymphatic system with an overall 5-year survival rate of 50–60% (statistics
vary depending on the cell type, stage of disease at diagnosis, and treatment). Indolent
lymphomas generally carry a good prognosis with a median survival of 10 years but a high
rate of relapse, and are usually not curable in advanced stages. Treatment for the indolent
forms includes periods of watchful waiting, radiation therapy and chemotherapy. By
comparison, 30–60% of individuals who convert to or present with aggressive forms of
NHL can be cured with intensive chemotherapy regimens, but the disease has a shorter
natural history, with the greatest risk of relapse within 2 years of treatment cessation.13
Thus, from a patient perspective, various forms of NHL are experienced as a life-long
chronic illness, with intermittent symptom-free and symptom exacerbation phases requiring
treatments.
Given the expected increase in NHL incidence rates14 attributed to the increasing average
age of the US population, the time has come to understand the health and QOL status and
needs of this population overall, and by survivorship status. Such information may suggest
areas for treatment or the targeting of scarce health care resources. Thus, this paper used
three outcome measures to compare the health and QOL status of those who report active
NHL disease with those who are short-term survivors (STS; 2–4 years post-diagnosis) and
long-term survivors (LTS; ≥5 years post-diagnosis) who report being in remission or cured.
Conceptual model
Figure 1 illustrates the conceptual model underlying this research which is based on coping
theories15 and empirical research.3,9,12,16–18 Clinical characteristics are conceptualized as
stressors, while survivor life-course factors are comprised of selective demographic, health
and psychosocial characteristics that may influence each other and the outcome of these
stressors. For example, quality of social support can affect an individual’s appraisal of
cancer’s impact on his/her life,18 which may either diminish or enhance individual coping
strategies and possibly lead to negative and/or positive QOL-related outcomes. Also,
individuals with active disease may be more likely to experience higher levels of clinical
stress than those who are in remission or cured.
METHODS
Participants and Procedures
Potential study participants were identified through the Duke and University of North
Carolina Tumor Registries and contacted by mail following Institutional Review Board and
physician approvals. NHL patients were eligible if they were at least 19 years old and 2
years post-diagnosis.
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Health Status and QOL Outcomes—Three measures were used to assess outcomes.
One, the SF-36, a general health measure of physical and mental health functioning, was
used to allow for comparisons to general population-based norms. It is comprised of 36
items representing eight sub-scales and two summary scores, the physical component (PCS)
and the mental component (MCS).19 For purposes of comparison, a score of 50 (SD=10.0)
represents the population mean.20 Reliability estimates ranged from α=.84-.95. Second, to
capture cancer-specific QOL, the 27-item Functional Assessment of Cancer Therapy
(FACT-G) and 15-item FACT-LYM module (lists lymphoma-related symptoms such as
fevers, night sweats, itching) were used.21 The FACT-G was originally intended for patients
in treatment, but is increasingly being used with off-treatment samples. Reliability statistics
for both ranged from α=.77–.93. Third, the Impact of Cancer (IOC) assessed respondents’
perceptions of positive and negative impacts of cancer in various aspects of their lives, using
5 positive and 5 negative subscales and two summary scores (Positive and Negative Impact).
18 The IOC was developed to assess certain aspects of survivorship not measured by other
QOL measures (e.g., health worries, meaning of cancer, post-traumatic growth).22
Reliability estimates ranged from α=.62–.91. Higher scores on all of the outcome measures
indicate better health status and QOL, except for the IOC Negative Impact, where higher
scores indicate greater negative impacts.
Demographic and Clinical Characteristics—Demographic (DEM; gender, race,
ethnicity, age, income, education, marital status, employment status) and clinical (CLN;
histology, stage, surgery, radiation therapy, chemotherapy, bone marrow/stem cell
transplant, biologic therapy, NHL treatment status, recurrence, number of oncology-related
visits, site of treatment) information was collected via self-report and the Tumor Registry
databases. NHL histology was categorized as indolent or aggressive based on the updated
REAL/WHO classification system.23
General Health (HTH)—The Self-administered Co-morbidity Questionnaire (SCQ)24 was
used to assess non-NHL health problems. In addition, selected questions related to
healthcare usage were adapted for use from the Childhood Cancer Survivor Study survey.25
Psychosocial (PSO)—The 20-item Medical Outcomes Study-Social Support Survey
measured perceived availability of social support26 (range 20–100; α=.97). The Appraisal of
Life Threat and Treatment Intensity Questionnaire (six items, range 6–30; α=.80) assessed
the extent to which cancer and its treatment are perceived to be life-threatening and intense.
27 Employment and insurance-related situations and difficulties were collected using 24
questions (possible range 0–24, α=.82) derived from a Cancer and Leukemia Group B
research instrument.28
Post-traumatic stress (PTS)—The Post-traumatic Stress Disorder (PTSD) Checklist
(PCL-C) assesses symptomatology in non-combat populations by presenting a symptom
checklist that closely mirrors DSM-IV criteria for a formal diagnosis of PTSD.29, 30 The
instructions were modified for the current study, such that survivors were asked to rate each
symptom in the past 4 weeks with respect to their diagnosis and treatment for lymphoma.
The continuous scoring method was used and Cronbach’s α ranged from .78-.91.
Statistical Methods
Descriptive statistics were used to estimate the health status and QOL means for this
population overall and by survivorship status (active disease, STS, LTS). Chi-square and
ANOVA were used to compare distributions and mean scores on outcome variables and the
covariates across the three survivor groups. The amount of missing data in income (10%)
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and stage (12%) variables justified multiple imputation via the Markov chain Monte Carlo
(MCMC);31 imputed values for disease status and outcome variables were not generated.
Twenty datasets containing imputed values were used in the multiple linear regression
analyses via the SAS MIANALYZE procedure.32 Multiple linear regressions were
conducted to examine the association between survivorship status and outcomes, adjusting
for covariates. For all comparisons, individuals with active disease were the reference group.
For each of the five outcome summary scores (PCS, MCS, FACT-G, IOC Positive, IOC
Negative), six sequential series of linear regression models were constructed to examine the
association with active disease such that each domain of covariates was added in order of
strength of association with the outcomes (correlations with DEM and CLN were small;
HTH were medium; and PSO and PTS were large). That is, the first model tested for the
relationship between active disease and disease-free status with summary scores without
accounting for covariates; then, subsequent models added DEM, CLN, HTH, PSO and PTS.
The order of entry had no bearing on the final results for each measure. Statistical analyses,
including tests for multi-collinearity, were carried out using SAS 9.1 software.
RESULTS
Seven hundred and sixty-one participants (74% response rate) provided informed consent.
Table 1 lists the information collected by total sample and survivorship status. Sample bias
analyses using demographic information from the registries indicated that participating
survivors were less frequently non-Caucasian and older at diagnosis and study enrollment
than non-participants (all P<.001). Survivors who reported having active disease were more
likely to have been diagnosed with an indolent lymphoma, received biologic therapy, had
more recurrences, types of treatment, and PTS than disease-free survivors (all P<.01). STS
were younger at enrollment, less likely to have a secondary cancer, and had less co-
morbidity than those with active disease or LTS (all P<.05). Although not detailed in Table
1, many reported receiving current treatment for co-morbid conditions, including high blood
pressure (34%), heart disease (17%), back pain (15%), osteoarthritis (15%), and depression
(13%). Fourteen percent of survivors reported a history of other non-skin cancers, including
prostate, breast, melanoma, colon, and bladder.
Bivariate analyses
Figure 2 displays the means and standard deviations for the outcome variables by disease
status. In terms of physical (PCS) and mental (MCS) health, those with active disease
demonstrated worse functioning when compared to disease-free survivors (all P≤.01). Those
with active disease also demonstrated significantly worse QOL as measured by the FACT-G
and lymphoma-specific items than both STS and LTS (all P<.01). Also, those with active
disease reported significantly less positive and more negative impact (all P<.01) via the IOC
than those who were disease-free. STS and LTS did not differ significantly in any of the
outcomes measured. Descriptive statistics for the outcome variables and their correlations
are presented in Table 2. All outcomes were significantly related to each other with the
exception of the IOC Positive Impact, which was related to the MCS (P<.05) and lymphoma
symptoms (P<.001) only.
When compared to general population-based norms (PCS and MCS; mean=50, SD=10),20
individuals with active disease scored lower in physical (mean=41.1, SD=11.9) and mental
(mean=45.4, SD=11.5) health. As expected, disease-free survivors fared better, but still
seemed to have worse physical health (STS, mean=47.3, SD=10.4; LTS, mean=45.7,
SD=9.9) than the general adult population.20 However, after comparing our disease-free
sample with their corresponding age-stratified normed groupings (25–34, 35–44, 45–54, 55–
64, 65–74, ≥75), our sample scored comparably (within ±1.8 points) on the PCS. Regarding
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mental health, scores from our disease-free survivors on the MCS (STS, mean=50.3,
SD=9.9; LTS, mean=49.3, SD=11.4) were close to the general population norm;20 however,
our sample scored lower (≤4.1 points) on the MCS than the corresponding age-stratified
groups (except for 35–44 and ≥75), with the largest difference between the 25–34 age
groups.20
Regression results
Tables 3a and 3b display the regression coefficients for the relationship between
survivorship status and health status and QOL as measured by the SF-36, FACT-G and IOC.
The coefficients for the series of six sequential models represent the increase in the mean
level of health status and QOL related to disease-free survivorship status, after adjusting for
the covariates. For example, the SF-36 Model I indicates that STS and LTS score 6.2 and
4.6 points higher respectively than those with active disease before adjusting for covariates
(P<.001). While statistically non-significant, LTS reported lower health status and QOL
than STS in all models.
SF-36—Consistent with bivariate analyses, Model I (Table 3a) indicates that disease-free
survivorship had a strong relationship to better PCS scores (P<.001). However, this
relationship quickly became non-significant after accounting for the CLN covariates. In
total, 48% of the variance was accounted for by all covariates. Similar to the PCS, the
relationship between disease-free survivorship and the MCS was significant (P<.01). Unlike
the PCS, significant differences persisted until the PTS covariate was added. A slightly
higher percentage (52%) of the variance was accounted for by all covariates.
FACT-G—Consistent with the SF-36, Model I (Table 3b) indicates that disease-free
survivorship had a strong relationship to better QOL scores (P<.001). The adjustment for the
DEM, CLN, HTH and PSO domains reduced the magnitude of the survivorship status
relationship, but in LTS remained significant until the addition of the PTS variable. A
sizable amount of the variance (68%) in this cancer-specific instrument was explained by the
covariates.
IOC—Consistent with the other outcome measures, disease-free survivorship had a strong
relationship to better IOC Positive Impact scores (P<.001), as indicated by Model I (Table
3b). The adjustment for the CLN covariates reduced the magnitude of the survivorship status
relationship, but remained significant (p<.05) through Model VI. The covariates explained
only 32% of the variance.
Significant differences based on disease status also were found with the IOC Negative
Impact scores. Similar to the Positive Impact scale, accounting for the CLN variables
reduced the magnitude of the survivorship status relationship. However, differences between
those with active disease and disease-free survivors became non-significant with the
addition of the PSO variables for STS and PTS variable for LTS. This model accounted for a
sizable 60% of the variance.
DISCUSSION
This study provides one of the first examinations of health status and QOL among NHL
survivors. Findings included a strong independent relationship between active disease and
all outcome measures. However, the relationship between survivorship status and most
outcomes became non-significant upon adjustment, which indicates that differences in these
measures based on active disease are essentially explained by associated differences in some
of the covariates. Only one outcome measure continued to elucidate differences between
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those with and without active disease: the IOC Positive Impact scale. One reason for this
might be that the IOC is the only QOL-related measure that contains items related to post-
traumatic growth; hence, it may be a more sensitive outcome measure for individuals who
are disease-free and more likely to report having benefited from their cancer experience.
Across most outcome measures there was evidence of moderation, where the inclusion of
the PTS covariate produced the largest increases in R2 except for the SF-36 PCS and IOC
Positive Impact models, where adding HTH and PSO covariates respectively produced the
largest increases. These data suggest that survivors indicating PTS are more likely to report
negative health status and QOL, as adjusting for this variable in Model VI erased the
difference between active disease and disease-free scores. Also, there was evidence that
HTH covariates (e.g., co-morbidity) played a pivotal role in explaining physical health status
and functioning and a lesser role in overall QOL. Further, the importance of PSO variables
(e.g., social support) is evident in the context of cancer-related QOL, as indicated by the
largest and second-largest increase in R2 in the IOC Positive Impact and FACT-G models
respectively. While the present study was not designed to determine the mechanisms linking
survivorship status and health and QOL-related outcomes, it is likely that active disease
contributes to worse outcomes through the increase in emotional and physical distress that is
associated with the disease and treatment-related effects.
Unexpectedly, no significant differences were found between STS and LTS on any of the
health or QOL measures, suggesting that simply time out from diagnosis and treatment is
not an explanation for such status after cancer, and that psychosocial effects resolve by or
continue beyond the conventional five-year threshold. Given this finding, survivorship
researchers might consider expanding their LTS population to include STS as a means to
increase sample size and thereby enhance the power of their statistical analyses. For
clinicians, this non-significant finding implies that screening for health and QOL-related
issues related to having had cancer should not conclude prior to the 5-years post-diagnosis
milestone for those who evidenced poor QOL earlier. Other critical elements, such as social
support or the alleviation of physical symptoms, play a key role in achieving enhanced
functioning, regardless of when these elements occur.
Our finding where most of our age-stratified subgroups scored lower on the MCS than the
norms (i.e., met criteria for minimally important difference)33 contrasts with prior studies in
which long-term survivors’ psychological health approximates that of healthy comparison
groups.2,4,34 The tentative health status of lymphoma patients and the knowledge that their
cancer could come back at any time may contribute to a more tenuous or labile emotional
health state. However, a difference of 4.1 points on the MCS is less than half the standard
deviation of 11.2 in our sample; therefore, the clinical relevance is small. Future studies are
needed to examine the clinical meaning of the lower MCS scores especially in a young
survivor cohort.
The relationship between having active disease and self-reported health status and QOL has
important implications. For example, health care professionals may want to give closer
attention to survivors with chronic (active) disease and screen for QOL-related problems. In
addition, psychosocial intervention design and development should consider balancing
treatment and control groups based on disease status. For example, individuals with active
disease may be more likely to report worse QOL at baseline and may respond differently to
specific treatment components than those who are disease-free. Finally, components of PSO
(less social support, negative appraisals, and more cancer-related insurance and
employment-related issues) and PTS were shown to be related to health status and QOL and
are potentially modifiable.
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There are several limitations in this study. As is typical for any cross-sectional study, we can
not establish a cause-effect relationship between survivorship status and health and QOL
status. For example, we cannot ensure that the risk factor (active disease) preceded the
variables of interest (health status, QOL) due to the inability to assess this cohort over time
as would be possible in a longitudinal design. Further, the sequential models adjusted for
many, although likely not all, of the characteristics that might have confounded the
relationship between survivorship status and outcomes. In addition, the inclusion of patients
from only two large comprehensive cancer centers in NC may limit the generalizability of
our results to survivors living in other regions and treated at smaller hospitals. However, our
demographic profile closely mirrors that of the national population of NHL survivors,35
thereby strengthening the robustness and generalizability of our analyses. Also, the IOC was
initially developed for and only tested with off-treatment survivors who are 5–10 years post-
diagnosis and appropriately might not be sensitive for those in active treatment, although
there are no data to support this. Also, without a matched comparison group based on socio-
demographic and co-morbid conditions it is difficult to determine if these survivors had
better or worse status than a similar group of people who never had cancer. However, the
results of comparisons to general population norms support the need to address health status
and functioning concerns in this population, as evidenced by lower PCS (for those with
active disease) and MCS scores in our sample. Finally, the lower percentage of those with
active disease (14%) implies less precise group mean score estimates compared to disease-
free survivors.
In summary, the use of general health status and cancer-specific measures revealed
significant differences between NHL survivors who reported having active disease and those
who were disease-free. In addition, there were no significant differences in outcomes
between STS and LTS, which challenges the current use of the 5-year mark in LTS research.
These data also illustrate the value of using multiple instruments to assess areas that are
particularly relevant to cancer survivors and of studying subgroups with differing disease
status.
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Figure 2. Health Status and Quality of Life in non-Hodgkin Lymphoma Survivors (n=761)
SF-36: Medical Outcomes Study-Short form; PCS: Physical Component Summary; MCS:
Mental Component Summary; FACT-G: Functional Assessment of Cancer Therapy-
General; FACT-LYM: Functional Assessment of Cancer Therapy-Lymphoma; IOC: Impact
of Cancer
Higher scores indicate better quality of life except for the IOC Negative Impact; error bars
represent 1 standard deviation from mean; comparisons between active and disease-free
survivors are statistically significant (all P< .01); no statistical difference between short-term
and long-term disease-free survivors (all P>.10).
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